What is Tirzepatide?

The compound and its status

Tirzepatide is a synthetic peptide carried under the development code LY3298176. On this site it sits in the metabolic category, which is a filing convention here and not a claim about what it does in a person.

Its regulatory position is worth stating precisely. Tirzepatide has been approved by a regulator for human use in at least one market. That is narrower than it sounds. Approval attaches to a specific product, from a specific manufacturer, at a specific strength, in the markets that granted it. It does not transfer to a vial of powder bought from a supplier who was not the applicant. Two things can share a molecule and share nothing else.

So the approval tells you the molecule has passed a regulatory review somewhere. It tells you nothing about the contents, purity, or labelling accuracy of any particular vial in front of you. This site cannot inspect your vial and does not try to.

What is modelled here and what is not

Tirzepatide is one of the compounds modelled end to end on this site. Half life, absorption, accumulation across repeated doses, and clearance after stopping are all computed rather than described in vague terms.

What those models do is arithmetic on a pharmacokinetic profile. They answer one form of question: given an input schedule, how does the modelled amount in the body change over time. They are not clinical predictions. A clearance curve is not a statement about how you will feel, and an accumulation curve is not a suggestion to reach any particular level.

The models do not cover the things most readers actually want to know. Whether Tirzepatide works for a given goal, what dose is appropriate, what side effects occur, who should avoid it, and how it interacts with anything else are clinical questions. This site has no medical review process. It will not answer them, and you should be suspicious of any unreviewed page that does.

Reading the concentration table

The table covers every vial size sold and every bacteriostatic water volume in common use. Three things in it are worth pulling out.

First, the water volume never changes how much peptide you have. A 10 mg vial contains 10 mg whether you add 1 mL or 3 mL. What changes is how spread out it is, and therefore how much liquid you draw for a given amount.

Second, different vial and volume pairs land on the same concentration. A 10 mg vial in 1 mL, a 20 mg vial in 2 mL and a 30 mg vial in 3 mL all give 10 mg/mL. A 10 mg vial in 2 mL and a 15 mg vial in 3 mL both give 5 mg/mL. If you are used to measuring a particular concentration, you can often reach it again from a different vial size by scaling the water.

Third, the spread is wide. The lowest value in the table, from a 10 mg vial in 3 mL, is 3.33 mg/mL. The highest, from a 60 mg vial in 1 mL, is 60 mg/mL. Concentrated solutions mean small draws, and small draws are harder to measure accurately.

The arithmetic of handling it

Reconstitution has one calculation. Concentration equals vial contents in milligrams divided by bacteriostatic water added in millilitres. That is the whole table.

Drawing a dose reverses it. Volume equals the amount you want divided by the concentration you made. The dose amounts appearing in supplier listings for Tirzepatide are 2.5, 5, 7.5, 10 and 15 mg. Those are listing figures, not guidance. They exist here so the arithmetic has something concrete to work on.

One practical consequence follows. Syringe graduations are finite, so if a calculated draw falls between marks, the error is proportionally larger on a concentrated solution than a dilute one. Choosing more water for the same vial is the lever that fixes this. The trade is that a fixed water volume across a larger vial produces a stronger solution, which is why the 60 mg vial reaches 60 mg/mL in 1 mL and only 20 mg/mL in 3 mL. Run your own numbers before you draw anything.

What we do not know

Tirzepatide is modelled end to end on this site: half life, absorption, accumulation and clearance are all computed.

This page answers arithmetic and handling questions. It does not tell you what dose to take, what to expect, or whether anything is appropriate for you, and there is no medical review behind it.

Common questions

Is Tirzepatide legal?

Tirzepatide has been approved by a regulator for human use in at least one market, which is a statement about the molecule and about specific approved products. It is not a statement about the status of research chemical vials, which varies by country and by seller. This site does not give legal advice.

How much bacteriostatic water should I add to a Tirzepatide vial?

There is no single correct volume. The table shows what each of 1, 2, 2.5 and 3 mL produces for every vial size sold. More water gives a lower concentration and a larger draw volume for the same amount of peptide, which is generally easier to measure accurately.

What dose of Tirzepatide should I take?

This page will not answer that. Dosing is a clinical decision and this site has no medical review. The amounts listed here, 2.5 through 15 mg, are figures that appear in supplier listings and are used as arithmetic inputs, not recommendations.

Does adding more water make it weaker?

No. The vial still contains the same milligrams of peptide. More water lowers the concentration, so any given amount occupies more liquid and you draw a larger volume. The total in the vial is unchanged.

Does this site model how long Tirzepatide stays in the body?

Tirzepatide is modelled end to end here, so half life, absorption, accumulation and clearance are computed rather than estimated loosely. Those outputs are arithmetic on a pharmacokinetic profile. They describe a model, not an individual person, and they are not a clinical prediction of effect.